Clinical trial
New Antipsychotic Strategies: Quetiapine and Risperidone vs. Fluphenazine in…
NCT00161018 · University of Maryland, Baltimore, Other · Completed
Key facts
| NCT number | NCT00161018 |
|---|---|
| Title | New Antipsychotic Strategies: Quetiapine and Risperidone vs. Fluphenazine in Treatment Resistant Schizophrenia |
| Lead sponsor | University of Maryland, Baltimore, Other |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Schizophrenia |
| Intervention type | Drug |
| Interventions | Quetiapine, Risperidone, Fluphenazine |
| Enrollment | 150 |
| Start date | Nov 1, 2003 |
| Primary completion | Nov 1, 2004 |
| Completion | Nov 1, 2004 |
| First posted | Sep 12, 2005 |
| Last update posted | Aug 19, 2019 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: